Unknown

Dataset Information

Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle.


ABSTRACT: The time to suppression of HIV-1 viremia to below the limit of detection of standard clinical assays is an important prognostic indicator for patients on highly active antiretroviral therapy (HAART). Recent clinical trials of the integrase inhibitor raltegravir have demonstrated more rapid viral decay than previously seen with reverse transcriptase (RT) or protease inhibitor-based regimens. Because of the therapeutic importance of drugs that target different steps in the virus life cycle, it is imperative to consider whether viral dynamics are affected by the stage of the viral life cycle at which an antiretroviral drug acts. We use a mathematical model to investigate the effects of various drug classes on the dynamics of HIV-1 decay and show that the stage at which a drug acts affects the

SUBMITTER: Sedaghat AR 

PROVIDER: S-EPMC2290747 | biostudies-literature | 2008 Mar

REPOSITORIES: biostudies-literature